Physician profile
Raman Sood
NPI 1740272459
$215,265.59
in general payments reported to CMS, 2019-2025
83 companies · $26K in 2025
The $26K reported for 2025 was more than what 90% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $21K · 2021: $29K · 2022: $35K · 2023: $50K · 2024: $29K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $73K · Consulting Fee: $19K · Food and Beverage: $9,960 · Travel and Lodging: $4,058 · Education: $37.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $72,566.00 |
| Consulting Fee | $18,577.50 |
| Food and Beverage | $9,960.42 |
| Travel and Lodging | $4,058.32 |
| Education | $37.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $135,939.41 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
| Astrazeneca Pharmaceuticals Lp | $13,677.26 | 2019-2025 | Enhertu, Calquence, Imfinzi |
| Genzyme Corporation | $6,938.82 | 2019-2025 | |
| Incyte Corporation | $6,690.10 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Epizyme, INC. | $6,195.72 | 2020-2022 | |
| Exelixis INC. | $6,096.25 | 2019-2025 | Cabometyx |
| Celgene Corporation | $4,933.78 | 2019-2025 | Reblozyl, Pomalyst |
| Janssen Biotech, INC. | $4,907.41 | 2019-2025 | Tecvayli, Erleada, Darzalex |
| Gilead Sciences, INC. | $4,763.68 | 2019-2025 | Trodelvy |
| Astellas Pharma US INC | $3,068.84 | 2019-2025 | Vyloy, Padcev, Xtandi |
| Glaxosmithkline, LLC. | $3,004.99 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Novartis Pharmaceuticals Corporation | $2,137.58 | 2019-2025 | |
| Rigel Pharmaceuticals, INC. | $1,650.40 | 2019-2024 | Tavalisse, Rezlidhia |
| Janssen Scientific Affairs, LLC | $1,619.19 | 2019-2023 | Rybrevant, Darzalex, Tecvayli |
| Aveo Pharmaceuticals, INC. | $1,286.58 | 2021-2025 | Fotivda |
Show all 83 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,215.31 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Bayer Healthcare Pharmaceuticals INC. | $1,158.67 | 2019-2024 | |
| Amgen INC. | $1,115.69 | 2019-2023 | Kyprolis, Xgeva, Vectibix |
| Pfizer INC. | $1,053.57 | 2019-2025 | |
| Beigene USA, INC. | $827.91 | 2021-2024 | Brukinsa |
| Lilly USA, LLC | $543.71 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Genentech USA, INC. | $465.13 | 2019-2025 | Tecentriq, Venclexta, Lunsumio |
| Kite Pharma, INC. | $419.37 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $418.86 | 2019-2025 | Fruzaqla, Ninlaro |
| Eisai INC. | $380.63 | 2019-2025 | |
| Abbvie INC. | $332.35 | 2019-2025 | Venclexta |
| Alexion Pharmaceuticals, INC. | $283.07 | 2019-2022 | |
| Daiichi Sankyo INC. | $269.55 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Novocure Gmbh | $200.00 | 2022 | |
| Sun Pharmaceutical Industries INC. | $198.08 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $182.01 | 2020-2025 | Zepzelca |
| Syndax Pharmaceuticals, INC. | $169.08 | 2025 | Revuforj |
| Array Biopharma INC | $161.91 | 2020-2025 | Mektovi, Braftovi, Tukysa |
| Regeneron Healthcare Solutions, INC. | $160.67 | 2022-2025 | Libtayo |
| Pharmacyclics LLC, An Abbvie Company | $148.24 | 2019-2023 | Imbruvica |
| Springworks Therapeutics, INC. | $140.54 | 2024-2025 | Ogsiveo |
| Beone Medicines USA, INC. | $129.45 | 2025 | Brukinsa, Tevimbra |
| Sirtex Medical INC | $128.98 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.95 | 2019-2022 | |
| Seagen INC. | $117.97 | 2020-2021 | |
| Clovis Oncology, INC. | $113.95 | 2019-2021 | |
| Morphosys, US INC. | $111.01 | 2021-2023 | Monjuvi |
| Horizon Therapeutics Plc | $110.72 | 2020 | |
| Pharmaessentia USA Corporation | $104.40 | 2022-2025 | Besremi |
| Emd Serono, INC. | $100.65 | 2021-2025 | Bavencio |
| Novo Nordisk INC | $94.24 | 2025 | Ozempic |
| Geron Corporation | $93.32 | 2025 | Rytelo |
| Apellis Pharmaceuticals, INC. | $85.74 | 2023-2025 | Empaveli |
| Adc Therapeutics America, INC. | $81.91 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $81.68 | 2019-2021 | |
| Acceleron Pharma, INC. | $75.10 | 2020-2021 | |
| Agios Pharmaceuticals, INC. | $74.81 | 2019-2020 | |
| Cti Biopharma Corp. | $62.28 | 2022-2023 | Vonjo |
| Mirati Therapeutics, INC. | $62.21 | 2023 | Krazati |
| US Oncology Corporate, INC. | $60.22 | 2023 | |
| Kyowa Kirin, INC. | $52.24 | 2019-2020 | |
| Puma Biotechnology, INC. | $49.26 | 2020-2025 | |
| Karyopharm Therapeutics INC. | $47.79 | 2020-2022 | |
| Ipsen Biopharmaceuticals, INC | $46.69 | 2022-2024 | Onivyde |
| Dova Pharmaceuticals | $34.46 | 2021 | |
| Legend Biotech USA INC. | $31.80 | 2025 | Carvykti |
| Tg Therapeutics, INC. | $31.12 | 2021-2022 | |
| Coherus Oncology, INC. | $30.94 | 2022 | |
| Pharmacosmos Therapeutics INC. | $30.06 | 2025 | Monoferric |
| Adaptive Biotechnologies Corporation | $27.43 | 2023-2025 | Clonoseq |
| Nuvation Bio INC. | $24.21 | 2025 | Ibtrozi |
| Fresenius Kabi USA, LLC | $23.18 | 2023 | Stimufend |
| Servier Pharmaceuticals LLC | $22.21 | 2023 | |
| Verastem, INC. | $19.89 | 2019 | |
| Deciphera Pharmaceuticals INC. | $19.85 | 2021 | |
| Genmab U.S., INC. | $19.76 | 2022 | |
| Myriad Genetic Laboratories, INC. | $18.57 | 2023 | Precisetumor |
| Myovant Sciences INC. | $18.31 | 2021 | |
| Sobi, INC | $17.84 | 2024 | |
| Stemline Therapeutics INC. | $17.63 | 2023 | Orserdu |
| Invivyd INC | $17.26 | 2024 | Pemgarda |
| Taiho Oncology, INC. | $16.98 | 2019 | |
| Tempus Ai, INC | $16.53 | 2024 | |
| Avyxa Pharma, LLC | $15.55 | 2025 | |
| Foundation Medicine, INC. | $14.68 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $13.68 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $12.75 | 2019 | |
| Acrotech Biopharma INC. | $11.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raman Sood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.